News

News

Research report about Solasia was updated by Shared Research Inc.
Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma (PDF 145 KB)
Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2020) (PDF 318 KB)
Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2020 (under IFRS) (PDF 282 KB)
IR Report (Bridge Report) about Solasia
Update on SP-04 (PledOx) (3rd Report) (PDF 114 KB)
Notice of the Resolutions Adopted at the 12th Annual General Meeting of Shareholders (PDF 48 KB)
Research report about Solasia was updated by Shared Research Inc.
Notice of the 12th Annual General Meeting of Shareholders (PDF 235 KB)
PledPharma Announces Update on SP-04 (PledOx) Clinical Study Information (PDF 72 KB)
Announcement Regarding Changes to Executive Management and Conclusion of New Business Agreement with Itochu (PDF 123 KB)
Business Overview of Pipeline Products (Fiscal Year Ended December 31, 2019) (PDF 314 KB)
Consolidated Financial Results for the Fiscal Year Ended December 31, 2019 (under IFRS) (PDF 421 KB)
Solasia Announces Exclusive Out-Licensing Agreement for episil oral liquid with Synex in South Korea (PDF 168 KB)
PledPharma AB Announces Update on SP-04 (PledOx) Clinical Study Information (PDF 69 KB)
Solasia Selected as a Loan Margin Trading Issue (PDF 70 KB)

Information for use of our products

The site you are about to access is intended to provide information for medical professionals in Japan. It is designed to allow users to better understand Solasia's products.

I have read and understood above

Page Top

SELECT YOUR LANGUAGE